Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, BioNTech : Phase 3 Study Shows High Efficacy of Covid-19 Vaccine Booster

10/21/2021 | 05:34am EST

By Colin Kellaher

Pfizer Inc. and BioNTech SE on Thursday said a Phase 3 study showed a booster dose of their Covid-19 vaccine in individuals 16 years of age and older saw a relative vaccine efficacy of 95.6% compared to those who didn't receive a booster.

The partners said a booster dose administered to those who had already received the primary two-dose series of their vaccine restored protection against Covid-19 to the high levels achieved after the second dose.

Pfizer and BioNTech said they plan to submit the data to regulatory agencies around the world to support licensure in the U.S. and other countries.

The U.S. Food and Drug Administration in September granted emergency approval of a third dose of the Pfizer/BioNTech vaccine for people 65 and older and certain other adults at high risk of severe illness. The agency Wednesday cleared the use of a booster dose in eligible individuals who completed a primary round with a different vaccine.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-21-21 0734ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -4.91% 334.48 Delayed Quote.331.48%
PFIZER, INC. 1.77% 54.68 Delayed Quote.45.97%
All news about BIONTECH SE
03:58pStocks Slide From Earlier Gains Wednesday as US Confirms First Case of Omicron Variant
MT
01:33pEquities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
01:24pMIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
12:50pCuba to upgrade homegrown COVID-19 vaccine to confront Omicron
RE
12:43pMIDDAY ETF UPDATE : Broad-Market ETFs Higher; US Stocks Led Higher by Energy, Financials i..
MT
12:33pUS Stocks Led Higher by Energy, Financials in Midday Trading
MT
12:08pGLOBAL MARKETS LIVE : Merck, Volkswagen, Salesforce, Roche, Mondelez...
11:10aWALL STREET STOCK EXCHANGE : The Fed takes a new stance
11:08aEuropean ADRs Move Sharply Higher in Wednesday Trading
MT
06:50aEU To Start Early COVID-19 Vaccinations For Children Aged Five To 11
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 474 M 19 777 M 19 777 M
Net income 2021 9 220 M 10 435 M 10 435 M
Net cash 2021 9 793 M 11 084 M 11 084 M
P/E ratio 2021 8,45x
Yield 2021 -
Capitalization 74 976 M 84 953 M 84 857 M
EV / Sales 2021 3,73x
EV / Sales 2022 3,23x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 310,43 €
Average target price 260,16 €
Spread / Average Target -16,2%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE331.48%84 953
GILEAD SCIENCES, INC.18.31%86 465
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530
BEIGENE, LTD.34.50%32 613